Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck, Kingston H. G. Mills
European Journal of Immunology (2017) Vol. 47, Iss. 5, pp. 765-779
Open Access | Times Cited: 480

Showing 1-25 of 480 citing articles:

Advances in the understanding and treatment of sepsis-induced immunosuppression
Fabienne Venet, Guillaume Monneret
Nature Reviews Nephrology (2017) Vol. 14, Iss. 2, pp. 121-137
Open Access | Times Cited: 693
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Xingzhe Ma, Enguang Bi, Yong Lu, et al.
Cell Metabolism (2019) Vol. 30, Iss. 1, pp. 143-156.e5
Open Access | Times Cited: 662
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Elham Alsahafi, Katheryn Begg, Ivano Amelio, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 8
Open Access | Times Cited: 438
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Simon Tiberi, Nelita du Plessis, Gerhard Walzl, et al.
The Lancet Infectious Diseases (2018) Vol. 18, Iss. 7, pp. e183-e198
Open Access | Times Cited: 328
Metal Drugs and the Anticancer Immune Response
Bernhard Englinger, Christine Pirker, Petra Heffeter, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1519-1624
Open Access | Times Cited: 302
Sex differences in cancer mechanisms
Joshua B. Rubin, J. S. Lagas, Lauren Broestl, et al.
Biology of Sex Differences (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 274
Current progress in innovative engineered antibodies
William R. Strohl
Protein & Cell (2017) Vol. 9, Iss. 1, pp. 86-120
Open Access | Times Cited: 252
The Role of PD-1 in Acute and Chronic Infection
Jil Marie Jubel, Zachary R. Barbati, C. Burger, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 228
An early history of T cell-mediated cytotoxicity
Pierre Golstein, Gillian M. Griffiths
Nature reviews. Immunology (2018) Vol. 18, Iss. 8, pp. 527-535
Closed Access | Times Cited: 227
Cardiotoxicity of immune checkpoint inhibitors
Gilda Varricchi, Maria Rosaria Galdiero, Giancarlo Marone, et al.
ESMO Open (2017) Vol. 2, Iss. 4, pp. e000247-e000247
Open Access | Times Cited: 226
Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K‐Akt signaling in gastric cancer
Cheng Zhang, Mengqi Zhang, Sai Ge, et al.
Cancer Medicine (2019) Vol. 8, Iss. 10, pp. 4766-4781
Open Access | Times Cited: 226
Switching from Apoptosis to Pyroptosis: Gasdermin-Elicited Inflammation and Antitumor Immunity
K. Tsuchiya
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 1, pp. 426-426
Open Access | Times Cited: 195
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 194
Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma
Nataliya Rohr‐Udilova, Florian Klinglmüller, Rolf Schulte‐Hermann, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 166
Therapeutic host-directed strategies to improve outcome in tuberculosis
Carly Young, Gerhard Walzl, Nelita du Plessis
Mucosal Immunology (2019) Vol. 13, Iss. 2, pp. 190-204
Open Access | Times Cited: 162
Chronic Implant-Related Bone Infections—Can Immune Modulation be a Therapeutic Strategy?
Elisabeth Seebach, Katharina F. Kubatzky
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 158
Single-cell RNA landscape of the osteoimmunology microenvironment in periodontitis
Yue Chen, Hua Wang, Qiudong Yang, et al.
Theranostics (2022) Vol. 12, Iss. 3, pp. 1074-1096
Open Access | Times Cited: 98
Exosome-Mediated Immunosuppression in Tumor Microenvironments
Qihui Xie, Jiqi Zheng, Jiayi Ding, et al.
Cells (2022) Vol. 11, Iss. 12, pp. 1946-1946
Open Access | Times Cited: 84
NK‐cell exhaustion, B‐cell exhaustion and T‐cell exhaustion—the differences and similarities
Kevin Roe
Immunology (2022) Vol. 166, Iss. 2, pp. 155-168
Open Access | Times Cited: 83
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Liying Li, Fan Zhang, Zhenyu Liu, et al.
Cancers (2023) Vol. 15, Iss. 1, pp. 321-321
Open Access | Times Cited: 63
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang
Cancer Letters (2023) Vol. 562, pp. 216182-216182
Closed Access | Times Cited: 55
Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review
Jennifer M. Yoest
ImmunoTargets and Therapy (2017) Vol. Volume 6, pp. 73-82
Open Access | Times Cited: 145
Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor
Joleen M. Hubbard, Axel Grothey
Drugs (2017) Vol. 77, Iss. 10, pp. 1091-1103
Closed Access | Times Cited: 144
What did we learn from CTLA‐4 insufficiency on the human immune system?
Noriko Mitsuiki, Charlotte Schwab, Bodo Grimbacher
Immunological Reviews (2018) Vol. 287, Iss. 1, pp. 33-49
Closed Access | Times Cited: 134
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention
Ben Wylie, Christophe Macri, Justine D. Mintern, et al.
Cancers (2019) Vol. 11, Iss. 4, pp. 521-521
Open Access | Times Cited: 124
Page 1 - Next Page

Scroll to top